CN115715200A - 新型双特异性抗cd3/cd20多肽复合物配制剂 - Google Patents
新型双特异性抗cd3/cd20多肽复合物配制剂 Download PDFInfo
- Publication number
- CN115715200A CN115715200A CN202180041422.1A CN202180041422A CN115715200A CN 115715200 A CN115715200 A CN 115715200A CN 202180041422 A CN202180041422 A CN 202180041422A CN 115715200 A CN115715200 A CN 115715200A
- Authority
- CN
- China
- Prior art keywords
- liquid formulation
- polypeptide complex
- seq
- antibody
- bispecific anti
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
本发明提供一种含有第一抗原结合部分和第二抗原结合部分的新型双特异性抗CD3/CD20多肽复合物配制剂，具体而言，其包括液体配制剂和冻干配制剂。
Description
PCT国内申请，说明书已公开。
Claims (18)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020107335976 | 2020-07-27 | ||
| CN202010733597 | 2020-07-27 | ||
| PCT/CN2021/108455 WO2022022464A1 (zh) | 2020-07-27 | 2021-07-26 | 新型双特异性抗cd3/cd20多肽复合物配制剂 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115715200A true CN115715200A (zh) | 2023-02-24 |
Family
ID=80037593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180041422.1A Pending CN115715200A (zh) | 2020-07-27 | 2021-07-26 | 新型双特异性抗cd3/cd20多肽复合物配制剂 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230279138A1 (zh) |
| EP (1) | EP4190352A1 (zh) |
| CN (1) | CN115715200A (zh) |
| CA (1) | CA3217391A1 (zh) |
| WO (1) | WO2022022464A1 (zh) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2749151A1 (en) | 2009-01-16 | 2010-07-22 | Glaxosmithkline Llc | Treatment of a cancer using a combination of bendamustine and an anti-cd20 antibody |
| US20140004037A1 (en) | 2012-01-19 | 2014-01-02 | Therapeutic Proteins, Inc. | Stabilization of the anti-cd20 antibody rituximab |
| TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| MX2020003087A (es) * | 2017-09-21 | 2020-08-17 | Wuxi Biologics Ireland Ltd | Anticuerpos anti-cd3epsilon novedosos. |
| JP7337079B2 (ja) * | 2018-02-15 | 2023-09-01 | マクロジェニクス，インコーポレーテッド | 変異型ｃｄ３結合ドメイン、及び疾患の治療のための併用療法におけるその使用 |
| WO2019228406A1 (en) * | 2018-05-29 | 2019-12-05 | Wuxi Biologics (Shanghai) Co., Ltd. | A novel anti-cd3/anti-cd20 bispecific antibody |
| WO2020084608A1 (en) * | 2018-10-22 | 2020-04-30 | Explore Bio 1 Ltd | Precursor bispecific antibody constructs and methods of use thereof |
| AU2019370339A1 (en) * | 2018-11-01 | 2021-06-10 | Shandong New Time Pharmaceutical Co., Ltd. | Bispecific antibody and use thereof |
-
2021
- 2021-07-26 US US18/007,012 patent/US20230279138A1/en active Pending
- 2021-07-26 WO PCT/CN2021/108455 patent/WO2022022464A1/zh active Application Filing
- 2021-07-26 EP EP21849910.1A patent/EP4190352A1/en active Pending
- 2021-07-26 CA CA3217391A patent/CA3217391A1/en active Pending
- 2021-07-26 CN CN202180041422.1A patent/CN115715200A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022022464A8 (zh) | 2022-03-03 |
| WO2022022464A1 (zh) | 2022-02-03 |
| EP4190352A1 (en) | 2023-06-07 |
| US20230279138A1 (en) | 2023-09-07 |
| CA3217391A1 (en) | 2022-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108779179B (zh) | Cd47抗体、其抗原结合片段及其医药用途 | |
| JP7132232B2 (ja) | Ｃｄ１３７及び腫瘍抗原に結合できる二重特異性結合分子並びにその使用 | |
| EP3221346B1 (en) | Antibodies comprising modified heavy constant regions | |
| US20240141059A1 (en) | Antibodies comprising modified heavy constant regions | |
| CN114395048A (zh) | Cd3结合抗体 | |
| TWI734916B (zh) | 一種pd-l1抗體藥物組合物及其用途 | |
| CN110538321B (zh) | 一种cd47抗体药物组合物及其用途 | |
| JP7257971B2 (ja) | 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用 | |
| CN111484555B (zh) | 新型双特异性cd3/cd20多肽复合物 | |
| TWI754211B (zh) | 新型雙特異性cd3/cd20多肽複合物 | |
| CN112512550A (zh) | 一种TGF-β受体融合蛋白药物组合物及其用途 | |
| US20220106400A1 (en) | Antibodies comprising modified heavy constant regions | |
| EP3892634A1 (en) | Anti-cd40 antibody, antigen binding fragment and pharmaceutical use thereof | |
| WO2019184935A1 (zh) | 抗cd27抗体、其抗原结合片段及其医药用途 | |
| EP3647323A1 (en) | Anti-gitr antibody, antigen-binding fragment thereof, and pharmaceutical use thereof | |
| KR20210121102A (ko) | 항-cd79b 항체, 이의 항원-결합 단편, 및 이의 약학적 용도 | |
| TW202330027A (zh) | 抗ｃｄ－４７抗體製劑 | |
| WO2021190582A1 (zh) | 一种抗ox40抗体药物组合物及其用途 | |
| WO2022022464A1 (zh) | 新型双特异性抗cd3/cd20多肽复合物配制剂 | |
| CN116234826A (zh) | Btla抗体 | |
| CN113975385A (zh) | 新型双特异性抗cd3/cd20多肽复合物配制剂 | |
| EP4004047A1 (en) | Modified fc-regions to enhance functional affinity of antibodies and antigen binding fragments thereof | |
| KR20220159989A (ko) | C19 c38 이중특이적 항체 | |
| IL301513A (en) | Antibodies able to bind to ROR2 and bispecific antibodies that bind to ROR2 and CD3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |